#United States #Menlo Park, California #Endovascular Engineering #Hēlo Thrombectomy #Pulmonary Embolism

Funding Boost for Pulmonary Embolism Treatment

Endovascular Engineering, Inc. (referred to as E2) has recently announced a successful fundraising initiative, securing an impressive $42 million in an oversubscribed Series B financing round. This funding marks a significant step forward for the company as it aims to enhance its next-generation technological platform designed for the removal of clots related to venous thromboembolism (VTE).

The investment was co-led by 415 Capital and S3 Ventures, with contribution from several notable investors including Panakès Partners and ML Healthcare. Founding investor Santé Ventures also played a key role, alongside global strategic investors and Cordis, which maintains its strategic collaboration with E2.

As the company makes strides in advancing treatments for Pulmonary Embolism (PE), the additional funds will empower E2 to accelerate its mission of transforming VTE treatment. Currently nearing the completion of its ENGULF pivotal trial, E2 is evaluating the effectiveness of the Hēlo™ PE Thrombectomy System and is poised to introduce significant solutions to address the critical unmet needs in interventional medicine.

CEO's Vision and Market Impact

Dan Rose, the CEO of Endovascular Engineering, expressed confidence in the financing, stating that it not only serves as a monetary injection but also validates the company's commitment to revolutionizing PE treatment. He remarked, "With robust backing from sophisticated healthcare investors like 415 Capital and S3 Ventures, we are excellently positioned to establish our Hēlo PE System as the gold standard in mechanical thrombectomy for pulmonary embolism."

Dr. Ruben Osnabrugge of 415 Capital emphasized the differentiated technology that E2 is developing, calling it a best-in-class therapy for PE, which is notably the third leading cause of cardiovascular mortality. The investment from 415 Capital reinforces their mission to advance novel therapies in the cardiovascular domain. Brian R. Smith, the Managing Director at S3 Ventures, also highlighted his admiration for E2’s platform technology, which he believes will significantly scale the mechanical thrombectomy market, ultimately aiding patient recovery and enhancing their quality of life.

Innovative Thrombectomy Solutions

One of the central components of E2's new technology is the Hēlo Thrombectomy System. This advanced system represents a groundbreaking approach to clot removal, featuring a patented dual-action mechanism. It integrates an efficient aspiration process with state-of-the-art mechanical clot disruption capabilities. Importantly, the Hēlo system can deliver substantial performance through its compact catheter, which allows for effective single-pass procedures, streamlining treatment processes for healthcare professionals.

E2's Commitment to Innovation

Endovascular Engineering remains dedicated to the transformation of VTE treatment through innovative medical technology. As a venture-backed company, E2 is on a mission to develop and deploy pioneering solutions to elevate the standard of care for clot removal. The company's technology merges clinical insights with engineering proficiency, aimed explicitly at overcoming the complex challenges associated with VTE intervention.

It's important to note that the Hēlo PE Thrombectomy System currently remains for investigational use only and is not yet approved for commercial distribution.

Information and Future Prospects

As E2 continues to chart its path towards groundbreaking developments, interested parties can learn more about their advancements and future initiatives by visiting their official website at www.endovascularengineering.com or following them on LinkedIn for updates. The investment from 415 Capital and S3 Ventures not only enhances E2's capabilities but establishes a promising horizon for innovative treatment solutions in the healthcare sector.